A Phase II clinical trial evaluating rontalizumab, a recombinant humanized monoclonal antibody to IFN-α for SLE is also ongoing (NCT00962832) (http://www.clinicaltrials.gov). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.